Clinical Trials

At Blueberry Therapeutics

Clinical Trial Icon

Blueberry Therapeutics Ongoing and Completed Clinical Trials

TrialStatus
Multi-centre, international, randomised, vehicle controlled, parallel-group, double-blinded Phase 2 trial of BB2603 topical treatment in subjects with distal subungual onychomycosis (DSO) of the toenail (BBTAF202).Trial BBTAF202 is actively recruiting patients in Europe (Clintrials.gov identifier NCT04188574, EudraCT identifier 2019-002098-68).
Click here for information on this clinical trial.
Early phase development, partly blinded, positive and vehicle controlled, randomised, non-inferiority investigation of the pharmacokinetics, safety
and efficacy of BB2603 cutaneous
hand-pump spray versus Lamisil®
spray and versus BB2603 vehicle
hand-pump spray in subjects with onychomycosis and associated tinea pedis (BBT120126032001)
Trial BBT120126032001 has completed (EudraCT identifier 2016-001242-25).
Click here for information on this clinical trial.

0
Drugs in our pipeline
0
Patents and exclusives licences
0
Billion dollars in commercial potential

Blueberry Therapeutics Ltd Blueberry Therapeutics, Mereside, Alderley Park,
Alderley Edge, Cheshire, SK10 4TG.